The SERENA-6 trial demonstrated that using ctDNA to detect ESR1 mutations and switching from an AI to an oral SERD before clinical progression significantly improves progression-free survival and quality of life. This proactive approach, while debated by the FDA, highlights a potential paradigm shift from reactive to preemptive treatment changes.
Beyond being a simple biomarker for oral SERD eligibility, clinicians are recognizing that the ESR1 mutation is a 'bad actor' associated with more aggressive disease. It increases cancer cell adhesion, makes circulating tumor cell clumps larger, and promotes liver-tropism, underscoring the need for early and effective intervention.
A key clinical insight from trials like EMERALD is that patients who remain on their first-line CDK4/6 inhibitor for at least 12 months are the most likely to benefit from subsequent oral SERD monotherapy. This duration acts as a surrogate for endocrine sensitivity and helps identify ideal candidates for single-agent treatment.
Even without formal trial data on sequencing, clinicians are beginning to prescribe one oral SERD after progression on another (e.g., vepdegestrant after imlunestrant). This practice is driven by a belief in targeting the driving ESR1 mutation and by patient-specific factors like toxicity aversion, highlighting a real-world clinical need.
Kaplan-Meier curves for oral SERD monotherapy show a sharp drop, with 60% of patients progressing in the first six months. In contrast, combining the SERD with a targeted partner like an mTOR or CDK4/6 inhibitor addresses cross-talk resistance pathways, leading to early curve separation and preventing this initial failure.
Experienced oncologists are improving the tolerability of the mTOR inhibitor everolimus by starting at 5mg or 7.5mg daily, rather than the 10mg label dose, for many patients. This practical, off-label dose adjustment has made the drug a more manageable and viable option for combination therapy in the modern era.
Data from older studies suggests that PI3K inhibitors and mTOR inhibitors (like everolimus) have distinct mechanisms and may not be cross-resistant. This allows clinicians to confidently sequence these agents, for example using everolimus after progression on a PI3K or AKT inhibitor, providing more lines of targeted therapy.
The LDERA trial showed early, significant benefit for adjuvant gerodestrant, an oral SERD. This positive result creates a clinical challenge: how to position this new agent relative to adjuvant abemaciclib, which has a proven overall survival benefit in high-risk patients but was not studied in combination with a SERD.
A significant, immediate use for adjuvant oral SERDs like gerodestrant will be for patients who cannot tolerate the arthralgias and other side effects of standard aromatase inhibitors (AIs). This addresses a large and challenging clinical problem, positioning SERDs as a key alternative for maintaining long-term adherence to endocrine therapy.
A subtle but significant quality-of-life benefit of oral SERDs over AIs is their mechanism allows for the safe use of topical vaginal estrogens. This is a major advantage for younger patients who struggle with genitourinary symptoms but cannot use estrogens with AIs due to the risk of systemic absorption and spillover effects.
A press release indicating the PERSEVERE trial failed to show superiority of a SERD+CDK4/6 over an AI+CDK4/6 in the first-line metastatic setting raises concerns for adjuvant trials. Since ESR1 mutations are rare in early-stage disease, the added benefit of a SERD over an AI might be overwhelmed by the potent effect of the CDK4/6 inhibitor.
While its IV administration is a hurdle, the pan-PI3K/mTOR inhibitor gedotolisib is clinically compelling because of its distinct safety profile. It causes significantly less hyperglycemia and diarrhea compared to oral PI3K inhibitors like alpelisib, making it an attractive option for patients where those specific toxicities are a major concern.